Drug Profile
Docetaxel polymeric micelle - Samyang Biopharmaceuticals Corporation
Alternative Names: B 5704; Docetaxel-PM; NanoxelM; SYP-0704ALatest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Squamous cell cancer
- Discontinued Bladder cancer
Most Recent Events
- 30 Dec 2022 Discontinued - Phase-III for Bladder cancer (Second-line therapy or greater) in South Korea (Intravesicular)
- 22 Mar 2022 Phase-III clinical trials in Breast cancer (Neoadjuvant therapy) in South Korea (IV) (NCT05207514)
- 01 Feb 2022 Samyang Biopharmaceuticals plans a phase III trial for Breast cancer (Neoadjuvant therapy) (IV) (NCT05207514)